Human Insulin Market 2020 Strategic Assessments – B. Braun, Becton, Dickinson, Biocon, Biodel, ELI Lilly, Julphar, NOVO Nordisk, Sanofi, Wockhardt, Ypsomed

By: X herald

The Human Insulin Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Click the link to get a Sample Copy of the Report:

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Human Insulin Market: B. Braun, Becton, Dickinson, Biocon, Biodel, ELI Lilly, Julphar, NOVO Nordisk, Sanofi, Wockhardt, Ypsomed and others.

Global Human Insulin Market Split by Product Type and Applications:

This report segments the market on the basis of Types are:

Insulin Analogs and Biosimilars
Human Insulin Biologics

On the basis of Application, the market is segmented into:

Short acting
Intermediate acting
Long acting
Pre-mix Insulin

Industry News:

RAS AL KHAIMAH, 26th August, 2018 (WAM) — Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has signed an agreement with leading global medical technology company BD (Becton, Dickinson and Company) to supply disposable insulin pens in the UAE. BD develops innovative technologies, services and solutions that help advance both the clinical process for healthcare providers and clinical therapy for patients, including a wide variety of insulin delivery devices for diabetics.

Through this agreement, Julphar’s human insulin formulations, including Jusline R, Jusline N and Jusline 30/70, will be available for administration through BD’s portfolio of BD Vystra disposable pens. In addition, the same device will be used for insulin analogues (insulin glargine and insulin lispro), which are still under development. Commenting on the announcement, Jerome Carle, General Manager of Julphar, said, “The global diabetes market is large and growing. Through our agreement with BD, we will be able to keep pace with the growth and further improve our position in this lucrative market, placing us among the top three players in the world.

01/14/2020 – INDIANAPOLIS, Jan. 14, 2020  — Eli Lilly and Company (NYSE: LLY) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection 100 units/mL). Both insulins will have 50 percent lower list prices compared to the branded versions and will be available by mid-April.

Lilly’s first lower-priced insulin, Insulin Lispro Injection (100 units/mL), was made available in May 2019 at a 50 percent lower list price than Humalog® (insulin lispro injection 100 units/mL). In November 2019, more than 67,000 people filled prescriptions for Insulin Lispro Injection, and approximately 10 percent of people using Humalog have transitioned to the lower-priced option. Insulin Lispro Injection is now distributed by all major U.S. wholesalers and can be ordered by any pharmacy. Lilly will begin negotiations immediately with wholesalers and payers to make these additional lower-priced insulins available.

Buy The Report:

Regional Analysis For Human Insulin Market:

For comprehensive understanding of market dynamics, the global Human Insulin market is analyzed across key geographies namely:

North America (United States, Canada and Mexico)
(Germany, France, UK, Russia and Italy)
(China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa
(Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Human Insulin Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2020–2026.                 

Following are major Table of Content of Human Insulin Market:

– Global Market Overview, Drivers, Restraints and Opportunities, Segmentation overview

– Global Market competition by top Players

– Analysis by Regions

– Consumption by Regions

– Consumption, By Types, Revenue and Market share by Types

– Consumption, By Applications, Market share (%) and Growth Rate by Applications

– Complete profiling and analysis of Players

– Industrial Chain, Sourcing Strategy and Downstream Buyers

– Marketing Strategy Analysis, Distributors/Traders

– Global Market Effect Factors Analysis

– Global Market Forecast

– Global Market Research Findings and Conclusion, Appendix, methodology and data source

Finally, all aspects of the Global Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects. The report supplies the international economic competition with the assistance of Porter’s Five Forces Analysis and SWOT Analysis.

For More Information On This Report, Please Visit:

We Offer Customization On Report Based On Specific Client Requirement:

– Free country Level analysis for any 5 countries of your choice.

– Free Competitive analysis of any 5 key market players.

– Free 40 analyst hours to cover any other data point.

Browse Related Reports:

Recombinant Human Insulin Market:

Human Insulin Drugs And Delivery Devices Market:

Protamine Zinc Recombinant Human Insulin Market:

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.


MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Irfan Tamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687 |

This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.